Silverberg Bernstein Capital Management LLC Acquires New Position in Niagen Bioscience, Inc. $NAGE

Silverberg Bernstein Capital Management LLC bought a new position in Niagen Bioscience, Inc. (NASDAQ:NAGE) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 125,262 shares of the company’s stock, valued at approximately $1,169,000. Silverberg Bernstein Capital Management LLC owned approximately 0.16% of Niagen Bioscience at the end of the most recent quarter.

Insider Buying and Selling at Niagen Bioscience

In other news, CFO Ozan Pamir acquired 4,465 shares of the business’s stock in a transaction dated Friday, November 14th. The stock was purchased at an average price of $6.81 per share, for a total transaction of $30,406.65. Following the completion of the transaction, the chief financial officer directly owned 7,372 shares in the company, valued at approximately $50,203.32. This trade represents a 153.59% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 9.39% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a research report on Wednesday, October 8th. Canaccord Genuity Group dropped their target price on shares of Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Finally, Wall Street Zen lowered Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 9th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Niagen Bioscience currently has an average rating of “Moderate Buy” and an average price target of $14.28.

Niagen Bioscience Stock Performance

NAGE stock opened at $6.29 on Thursday. Niagen Bioscience, Inc. has a one year low of $5.16 and a one year high of $14.69. The company’s fifty day moving average price is $6.98 and its 200-day moving average price is $9.39. The company has a market capitalization of $502.00 million, a PE ratio of 26.21 and a beta of 2.31.

Niagen Bioscience (NASDAQ:NAGE) last posted its earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. The company had revenue of $33.99 million during the quarter, compared to analysts’ expectations of $31.30 million. Niagen Bioscience had a net margin of 16.38% and a return on equity of 24.13%.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.